title: [Effect of Zhifei mixture combined western drugs on symptoms and signs of children with mycoplasma pneumonia].
abstract: OBJECTIVE
  To observe the effect of three Chinese medical formulae (Zhifei Mixture I , Zhfei Mixture II, and Zhifei Mixture II) on main and secondary symptoms and signs of children with Totally 70 mycoplasma pneumonia in treating three types of children mycoplasma pneumonia.
  
  
  METHODS
  children with mycoplasma pneumonia were assigned to the control group (38 cases) and the treatment group (32 case). All patients were intravenously injected with Azithromycin and took Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution. Those in the treatment group additionally took Zhifei Mixture I , Zhfei Mixture II, and Zhifei Mixture Ill by syndrome typing. Their main and secondary symptoms and signs were observed before and after treatment (main symptoms and signs covered fever, cough, abundant sputum, short breath, and anoxia; secondary symptoms and signs covered aversion to cold, heart rate, facial complexion, spirit, appetite, and sweating).
  
  
  RESULTS
  Seven patients were lost in this study. Compared with before treatment in the same group, scores for main and secondary symptoms and signs decreased in the treatment group (P <0.01). The therapeutic effect on fever and cough was obviously better in the control group (P <0.01). The main and secondary symptoms and signs were more obviously improved in the treatment group than in the control group (P <0.01). Commpared with the control group, scores for main and secondary symptoms and signs decreased more in the treatment group (P <0.01). Patients' main and secondary symptoms and signs were more obviously improved (P <0.05).
  
  
  CONCLUSIONS
  Zhifei Mixture combined Western drugs could significantly improve main and secondary symptoms and signs of mycoplasma pneumonia children patients. Its efficacy was superior to that of using Western medicine alone.
authors.forename: Yan-Qing
authors.initials: YQ
authors.lastname: Yao
authors.forename: Zi-Wei
authors.initials: ZW
authors.lastname: Wang
authors.forename: Ying-Xue
authors.initials: YX
authors.lastname: Ding
authors.forename: Yang
authors.initials: Y
authors.lastname: Yu
authors.forename: Wen-Xing
authors.initials: WX
authors.lastname: Jiang
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Liu
authors.forename: Zhong-Hao
authors.initials: ZH
authors.lastname: Zhang
authors.forename: Hong
authors.initials: H
authors.lastname: Cui
mesh_terms: D000551:Ambroxol / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017963:Azithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002976:Clenbuterol / Q000008:administration & dosage / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005100:Expectorants / Q000008:administration & dosage / Q000627:therapeutic use; D005334:Fever; D006801:Humans; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy*; D013577:Syndrome
chemical_list: D000900:Anti-Bacterial Agents; D001993:Bronchodilator Agents; D004365:Drugs, Chinese Herbal; D005100:Expectorants; D000551:Ambroxol; D017963:Azithromycin; D002976:Clenbuterol